With its $13.6 billion acquisition of Life Technologies finally wrapped up, Thermo Fisher posted huge gains in revenue and profit in its first quarter as a combined company, raising the stakes for 2014 as it plans for more growth.
GE Healthcare completed its acquisition of three Thermo Fisher Scientific units. The $1.1 billion deal gives GE access to Thermo Fisher's profitable cell culture, gene modulation and magnetic bead businesses, helping the company expand its presence in protein analysis and medical diagnostics.
Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity. The top deals announced or closed in 2013 created...
Thermo Fisher has closed its mammoth $13.6 billion buyout of Life Technologies, barely a few days after U.S. antitrust regulators signed off on the deal.
Thermo Fisher Scientific grew revenue solidly but watched net income decline at the end of 2013, hit by extra costs stemming from acquisitions and reorganization.
Thermo Fisher has finally grabbed what it needed to close its $13.6 billion bid for Life Technologies – U.S. antitrust approval. But there are strings attached. For the deal to go through, the Massachusetts laboratory equipment giant must sell some divisions to GE Healthcare in an arrangement that mirrors similar agreements with European and Chinese regulators.
Thermo Fisher has cleared yet another hurdle in its bid to buy life technologies for $13.6 billion, with news today that China's Commerce Ministry has signed off on the deal.
Quest Diagnostics, which is facing a challenging reimbursement environment that's dampening sales, has signed three deals that the New Jersey company says will enhance its ability to develop next-generation diagnostic devices.
After nearly 9 years of legal back-and-forth, Enzo Biochem is still reaping rewards from its lawsuit against Life Technologies, picking up another $12.4 million in damages and bringing its total haul to more than $61 million, the company said.
When Thermo Fisher Scientific announced a $3.2 billion bond offering Wednesday, Fitch Ratings promptly lowered the medical device maker's credit rating to BBB and Moody's Investors Service said it likely will do the same.